Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
72.00
-0.68 (-0.94%)
Nov 13, 2026, 4:00 PM EST - Market closed
Monopar Therapeutics Employees
Monopar Therapeutics had 22 employees as of December 31, 2025. The number of employees increased by 6 or 37.50% compared to the previous year. That makes Monopar Therapeutics the 38,200th largest employer in the world and 5,430th in the United States.
Employees
22
Change (1Y)
6
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$936,528
Market Cap
487.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 6 | 37.50% | 22 | 0 |
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| Arvinas | 246 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Shattuck Labs | 40 |
| DiaMedica Therapeutics | 35 |
MNPR News
- 3 days ago - Cantor upgrades Monopar Therapeutics on recent pullback, added clarity - TheFly
- 3 days ago - Monopar Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald - TheFly
- 3 days ago - Monopar Therapeutics reports Q3 EPS (72c), consensus (85c) - TheFly
- 3 days ago - Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 days ago - Monopar Therapeutics Quarterly report: Q3 2026 - Filings
- 3 days ago - Monopar Therapeutics Earnings release: Q3 2026 - Filings
- 6 days ago - Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026 - GlobeNewsWire
- 13 days ago - Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - GlobeNewsWire